Skip to main content
padlock icon - secure page this page is secure

Recent Patents on Drugs Addressing Neurodegenerative Diseases

Buy Article:

$63.00 + tax (Refund Policy)

Considerable evidence gained in the past decade has supported a better understanding and management of neurodegenerative diseases, in the face of the continuous increase of their prevalence in the world. Inflammation, mitochondrial dysfunction and oxidative stress are now recognized to be hallmarks of all neurological disorders. Along with therapies targeting these features, new therapeutic strategies are emerging, based on microRNA, vaccination, generation and graft of neurons, as well as therapies based on multifaceted drugs. Are also taken into account vectors designed to deliver large molecule pharmaceuticals or genes across the blood-brain barrier. Current treatments are mainly symptomatic, therefore it is hoped that therapies based on patents described in the present review will lead to really curative treatments.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Cannabinoid receptors; Cholinesterase inhibitors; Growth factor-like proteins; MITOCHONDRIAL DYSFUNCTION; Neurodegenerative diseases; Pyrimidine nucleotide precursor; experimental autoimmune encephalomyelitis; infiltrating leukocytes; neuroinflammation; new therapeutic strategies; patents; therapy

Document Type: Research Article

Publication date: January 1, 2013

More about this publication?
  • Recent Patents on Biomarkers publishes review and research articles, and guest edited thematic issues on important recent patents on biomarkers. The coverage includes novel biomarkers in basic, medical, environmental, and pharmaceutical research. A selection of important and recent patents on biomarkers is also included in the journal. The journal is essential reading for all researchers involved in biomarker research and discovery. The journal also covers recent research (where patents have been registered) in fast emerging patent biomarker applications; discovery and validation are covered for drug discovery, clinical development and molecular diagnostics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more